Intitiation of satralizumab during pregnancy for successful childbirth in neuromyelitis optica spectrum disorder: A case report and literature review.
Tomoya Hasegawa, Takashi Ando, Hiroshi Sekikawa et al.
✦ AI-curated · Sources linked
Case in brief
A 32-year-old woman with neuromyelitis optica spectrum disorder (NMOSD) initiated satralizumab at 28 weeks of gestation to prevent relapse during pregnancy. She had been on low-dose prednisolone prior to conception. The patient delivered vaginally at 40 weeks without complications or disease relapse, and the neonate developed normally.
What made this case unusual
This case uniquely demonstrates the initiation of satralizumab during pregnancy for NMOSD management, highlighting its potential safety and efficacy in this context.
Diagnostic / clinical pearl
Clinicians should consider the use of satralizumab during pregnancy for patients with NMOSD to mitigate relapse risk, as it appears to be safe for both mother and child.
Why it matters
This case contributes to the limited knowledge on the use of biologic therapies during pregnancy, suggesting that satralizumab may be a viable option for managing NMOSD in pregnant patients.